Pfizer checks if new atirmociclib tablet matches the old one
NCT ID NCT07130097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested whether a new, higher-dose tablet of the cancer drug atirmociclib works the same in the body as the current tablet. Thirty-five healthy adults each received a single dose of both tablet forms after a meal, in random order. The goal was to see if the two formulations are bioequivalent, meaning they are absorbed and processed similarly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atirmociclib (PF-07220060)
- What this could lead to
- If successful, this study could confirm that a higher-dose tablet works the same as the current one, potentially simplifying manufacturing or dosing.
- What could go wrong
- This is a small, early-phase study in healthy people, not patients. It only checks how the drug is absorbed, not whether it treats any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does drug particle size matter? a study puts prifetrastat to the test
- Smoking may weaken dental fillings, new study suggests
- Pfizer tests drug interaction in tiny early study
- Pfizer tests heart drug safety in healthy volunteers
- Can a drug and probiotic combo turn back the clock on aging?
- Ibuzatrelvir drug study in healthy chinese volunteers completed